AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2019
Dec 13, 2019
30849_dirs_2019-12-13_2d43224b-13e0-4b00-8665-b2f678f8b965.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2019-12-11
Reporting Person: Foley Todd (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-12-11 | Common Stock | S | 13600 | $25.14 | Disposed | 2397259 | Indirect |
| 2019-12-12 | Common Stock | S | 3762 | $25.01 | Disposed | 2393497 | Indirect |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The shares were sold as follows: 13,091 by MPM BioVentures V, L.P. ("BV V") and 509 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F3: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $25.00 to $25.50. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: Shares are held as follows: 2,307,613 by BV V and 89,646 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5: Shares were sold as follows: 3,621 by BV V and 141 by AM BV5.
F6: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $25.00 to $25.06. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7: Shares are held as follows: 2,303,992 by BV V and 89,505 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.